At the last check on Friday, ImmunityBio Inc.’s (NASDAQ:IBRX) stock was up $0.07, moving up 3.80 percent to $1.91. The average number of shares traded per day over the past five days has been 1,700,571 shares. 3 times new highs have been achieved over the past 5 days, with a $0.0850 gain in that time frame. In the last twenty days, the average volume was 2,481,328, while in the previous 50 days, it was 2,391,655.
Since last month, IBRX stock retreated -33.91%. Shares of the company fell to $1.6500 on 08/11/23, the lowest level in the past month. A 52-week high of $7.80 was reached on 05/09/23 after having rallying from a 52-week low of $1.21. Since the beginning of this year, IBRX’s stock price has dropped by -62.33% or -$3.1550, and marked a new high 4 times. However, the stock has declined by -75.51% since its 52-week high.
IBRX stock investors should be aware that ImmunityBio Inc. (IBRX) stock had its last reported insider trading activity 74 days ago on Jun 05. BLASZYK MICHAEL D, the Director of the company, purchased of 71,915 shares for $2.75 on Jun 05. It resulted in a $198,023 investment by the insider. Brennan John Owen added 25,000 shares at an average price of $2.83 on Jun 02. The insider now owns 25,000 shares following the transaction. On Jun 01, Director Clark Wesley bought 7,000 shares at $2.91 apiece. The transaction was valued at $20,370.
Financial Health
In the three months ended June 29, ImmunityBio Inc.’s quick ratio stood at 0.10, while its current ratio was 0.10, showing that the company is not able to pay off its debt. Based on annual data, IBRX earned $351.54 million in gross profit and brought in $0.24 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -154.60%. Return on equity (ROE) for the past 12 months was 92.60%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. IBRX’s revenue fell 0.0% to $0.36 million during the quarter, while net income inched up to $40000.0. While analysts expected ImmunityBio Inc. to report -$0.23 quarterly earnings, the actual figure was -$0.32 per share, beating the consensus estimate by -39.10%. During the quarter, the company generated -$68.17 million in EBITDA. The liabilities of ImmunityBio Inc. were 936.41 million at the end of its most recent quarter ended June 29, and its total debt was $819.26 million. The value of shareholders’ equity is $456.25 million.
Technical Picture
This quick technical analysis looks at ImmunityBio Inc.’s (IBRX) price momentum. With a historical volatility rate of 96.22%, the RSI 9-day stood at 42.55% on 17 August.
With respect to its five-day moving average, the current ImmunityBio Inc. price is up by +4.64% percent or $0.0850. At present, IBRX shares trade -31.85% below its 20-day simple moving average and +11.99% percent above its 100-day simple moving average. However, the stock is currently trading approximately -37.21% below its SMA50 and -65.18% below its SMA200.
Stochastic coefficient K was 39.87% and Stochastic coefficient D was 36.38%, while ATR was 0.1872. Given the Stochastic reading of 49.07% for the 14-day period, the RSI (14) reading has been calculated as 40.31%. As of today, the MACD Oscillator reading stands at 0.0583.
Analyst Ratings
ImmunityBio Inc. downgraded its rating on ImmunityBio Inc. (NASDAQ: IBRX) to a Neutral in a note to investors on May 12, 2023. The analysts firm previously had an Overweight rating on the stock.ImmunityBio Inc. (IBRX) has been rated Overweight by analysts. According to 0 brokerage firms, IBRX is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate ImmunityBio Inc. stock as buy, with 1 recommending it as overweight.
With a median target price of $4.50, the current consensus forecast for the stock is $4.00 – $5.00. Based on these forecasts, analysts predict ImmunityBio Inc. (IBRX) will achieve an average price target of $4.50.
